Altered vancomycin pharmacokinetics in obese and morbidly obese patients: what we have learned over the past 30 years
Author:
Open Access
- 1 March 2012
- journal article
- review article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 67 (6) , 1305-1310
Abstract
Vancomycin was the first glycopeptide antibiotic introduced into clinical practice. Despite the numerous benefits of vancomycin, clinicians have struggled to dose vancomycin successfully in obese patients to achieve a therapeutic concentration for optimal bacterial killing. Owing to the hydrophilicity of vancomycin and the increase in both adipose tissue and muscle mass associated with obesity, the volume of distribution of vancomycin in obese patients is likely to be altered compared with non-obese patients. In addition to an increase in body mass, obesity is associated with an increase in certain circulating proteins, which results in altered free serum vancomycin concentration. Another alteration that occurs in obesity is increased blood flow secondary to increased cardiac output and blood volume, resulting in increased vancomycin clearance in obese patients. Vancomycin pharmacokinetics in the obese population remain an area of much debate, one that requires continued research given the rising number of obese patients in both the USA and worldwide.Keywords
This publication has 29 references indexed in Scilit:
- Refining Vancomycin Protein Binding Estimates: Identification of Clinical Factors That Influence Protein BindingAntimicrobial Agents and Chemotherapy, 2011
- Effect of Obesity on the Pharmacokinetics of Drugs in HumansClinical Pharmacokinetics, 2010
- Global burden of obesity in 2005 and projections to 2030International Journal of Obesity, 2008
- Predictability of vancomycin trough concentrations using seven approaches for estimating pharmacokinetic parametersAmerican Journal of Health-System Pharmacy, 2006
- Quantification of Lean BodyweightClinical Pharmacokinetics, 2005
- A Standard Weight Descriptor for Dose Adjustment in the Obese PatientClinical Pharmacokinetics, 2004
- Changes in the Serum Protein Binding of Vancomycin in Patients with Methicillin-Resistant Staphylococcus aureus InfectionTherapeutic Drug Monitoring, 1995
- Hepatic Free Fatty Acids in Alcoholic Liver Disease and Morbid ObesityHepatology, 1983
- Single‐Dose Kinetics of Intravenous VancomycinThe Journal of Clinical Pharmacology, 1980
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976